Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ABBV crawled date : 2021 - 06 - 04 save search
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights– Virtual investor event to take place on Monday, June 7, 2021 at 6 p.m. ET –
Published: 2021-06-04 (Crawled : 23:00) - biospace.com/
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
CHRS | $2.22 -0.45% -0.45% 2.2M
|
Health Technology
|
| O: 7.36%
H: 1.43%
C: -5.21%
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights
Published: 2021-06-04 (Crawled : 22:00) - globenewswire.com
CHRS | $2.22 -0.45% -0.45% 2.2M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
| Email alert
Add to watchlist
bioscience
Global $53 Bn Psoriasis Drugs Markets 2021-2030: Biologic Drugs, Small-Molecule Systemic Drugs, Topical Therapies, TNF-Alpha, PDE4, & Interleukin Inhibitors, Oral, Parenteral, Topical
Published: 2021-06-04 (Crawled : 21:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.63 -1.48% 0.0% 3.2M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
| Email alert
Add to watchlist
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
| Email alert
Add to watchlist
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
| Email alert
Add to watchlist
drug psoriasis therapy
Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
Published: 2021-06-04 (Crawled : 13:15) - prnewswire.com
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
leukemia
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2021-06-04 (Crawled : 01:00) - globenewswire.com
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.17%
H: 0.63%
C: -0.04%
CHRS | $2.22 -0.45% -0.45% 2.2M
|
Health Technology
|
| O: 7.36%
H: 1.43%
C: -5.21%
treatment therapy
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.